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ABSTRACT 
An improved, highly sensitive UPLC-MS/MS method has been developed for the determination of clarithromycin in human plasma. 
For sample preparation, liquid-liquid extraction with n-hexane:  methyl tert-butyl ether (20:80, v/v) mixture was carried out using 
clarithromycin 13C-d3 as the internal standard (IS). Acquity UPLC BEH C18 (50 mm × 2.1 mm, 1.7 µm) analytical column was used 
for chromatography with methanol-5.0 mM ammonium formate, pH 3.0 (78:22, v/v) as the mobile phase under isocratic conditions.  
The analysis time was 1.5 min. Quantitation of analyte was done by tandem mass spectrometer using electrospray ionization in the 
positive mode. The precursor → product ion transitions monitored for clarithromycin and IS were m/z 748.9 → 158.1 and m/z 752.8 
→ 162.0 respectively. The method was validated over a dynamic concentration range of 0.80-1600 ng/mL with correlation coefficient 
(r2) ≥ 0.9998. The mean extraction recovery of clarithromycin was 96.2 % across six quality control levels. Intra-batch and inter-batch 
accuracy and precision (% CV) ranged from 96.8 to 103.5 % and 1.28 to 4.85 % respectively. Stability of clarithromycin in plasma 
was evaluated under different conditions like bench top, auto sampler, dry and wet extract, freeze-thaw and long term. The present 
method was successfully applied to a bioequivalence study in 20 healthy subjects who received single oral dose 250 mg 
clarithromycin tablet formulation. The reproducibility of the method was investigated by reanalysis of 100 incurred samples.  
            Keyword: Clarithromycin, clarithromycin 13C-d3, UPLC-MS/MS, human plasma, sensitive, bioequivalence 
 
 
INTRODUCTION  
Clarithromycin (6-O-methylerythromycin, CLA) is a 
semi-synthetic 14-membered macrolide useful for the treatment of 
a number of bacterial infections. It is active against several 
Gram-positive (Staphylococcus aureus, Streptococcus 
pneumonia, Streptococcus pyogenes) and Gram-negative 
(Haemophilus influenza, Haemophilus parainfluenzae, Moraxella 
catarrhalis) bacteria and other microorganisms like Mycoplasma 
pneumonia, Chlamydia pneumonia, Mycobacterium avium and 
Mycobacterium intracellulare [1,2]. The macrolides are a group 
of antibiotics whose activity is due to the presence of a large 
macrocyclic lactone ring which has one or more deoxy sugars, 
usually cladinose and desosamine [3]. CLA is rapidly absorbed 
from the gastrointestinal tract after oral administration and has an 
absolute bioavailability of ~ 50%. It is mainly metabolized by 
cytochrome P450 (CYP) 3A enzymes (CYP3A4 and CYP3A5) to 
an active 14-hydroxy metabolite. The plasma protein binding of 
CLA is about 65-70 % and the maximum plasma concentration is 
attained within 2-4 h [2, 4]. 
 Literature presents several methods to determine CLA either as 
a single analyte [5-13], or together with its metabolite and other 
antibiotics [14-20] in different biological matrices like human 
plasma [5-7, 10-13, 15, 17, 18], rat plasma [8, 16], human serum 
[9, 14], human urine [11], gastric juice and gastric tissues [16], 
horse plasma, epithelial lining fluid and broncho-alveolar cells 
[19] and dried blood spots [20]. In these methods different 
analytical techniques like capillary electrophoresis [11], HPLC 
with electrochemical [5, 15, 16], UV [7, 8], fluorescence [9, 14], 
and mass spectrometric detection [6, 10, 12, 13, 17-20] have been 
employed. Amongst these only one UPLC-MS/MS based method 
has been reported with a linear range of 1.0-3000 ng/mL in human 
plasma [13]. This method presents a chromatographic run time of 
2.0 min with 200 µL plasma volume for processing. A 
comparative summary of salient features of methods developed in 
human plasma is presented in Table 1.  
In the present work we report an improved UPLC-MS/MS method 
for determination of CLA in human plasma with respect to the 
sensitivity, analysis time and plasma sample volume over existing 
methods. Further, the method employs a deuterated internal 
standard for better accuracy and precision of the data. The method 
was applied to a bioequivalence study in 20 healthy subjects using 
250 mg clarithromycin tablets.      
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Table 1 Comparative assessment of chromatographic methods developed for clarithromycin in human plasma 
Sr. 
No. 
Technique;  
Linear range 
(ng/ml)   
Extraction procedure; 
internal standard  
Sample 
volume 
(µL) 
Retention 
time; run 
time (min) 
Application  Ref. 
1 HPLC-electr
o-chemical;  
100-4000  
PP with membrane syringe; 
roxithromycin  
120 15.3; 30.0 Pharmacokinetic study in 4 healthy 
volunteers with a single oral dose of 
500 mg clarithromycin tablet  
5 
2 HPLC-MS/
MS; 
2.95-20016  
LLE with n-hexane-ethyl 
acetate; roxithromycin  
300 1.88; 3.0 Pharmacokinetic study in 9 healthy 
volunteers with a single oral dose of 
500 mg clarithromycin tablet 
6 
3 HPLC-UV;  
31.25-2000  
LLE with 
n-hexane-1-butanol and back 
extraction with acetic acid; 
norverapamil 
1000 8.37; 10.0  Bioequivalence study with different 
250 mg tablet formulations of 
clarithromycin in 14 healthy 
volunteers 
7 
4 LC-MS/MS;  
10-5000   
PP with acetonitrile; 
telmisartan  
50 1.76; 2.4 Bioequivalence study with 500 mg 
tablet formulations of clarithromycin 
in 20 healthy volunteers 
10 
5 LC-MS/MS;  
100-5000  
PP with acetonitrile in 96 
well plate; roxithromycin 
25 1.20; 1.75  Pharmacokinetic study in 6 healthy 
volunteers with 500 mg tablet 
formulation of clarithromycin  
12 
6 UPLC-MS/
MS;  
1-3000  
LLE with diethyl ether; 
roxithromycin 
200 < 1.0; 2.0  Pharmacokinetic study in 18 healthy 
volunteers with 500 mg tablet 
formulation of clarithromycin 
13 
7 HPLC-electr
oche-mical; 
100-10000  
PP with methanol and 
acetonitrile followed by SPE; 
roxithromycin 
500 ~13.0; 19.0 Study on eluant composition and 
column temperature for reproducible 
electrochemical response 
15 
8a LC-MS/MS;  
36.5-5066.2  
PP with acetonitrile; 
erythromycin   
200 1.30; 2.0  Bioequivalence study with 500 mg 
tablet formulations of clarithromycin 
in 40 healthy volunteers 
17 
9b LC-MS/MS;  
100-10000 
PP with methanol and 
acetonitrile; 
cyanoimipramine 
100 ~2.5; 3.5 -- 18 
10 UPLC-MS/
MS;  
0.8-1600 
LLE with n-hexane-methyl 
tert-butyl ether; 
clarithromycin 13C-d3 
100 1.01; 1.50 Bioequivalence study with 250 mg 
tablet formulations of clarithromycin 
in 20 healthy volunteers; incurred 
sample reanalysis with 100 samples 
PM 
          aAlong with 14-hydroxy clarithromycin; bAlong with 14-hydroxy clarithromycin, rifampicin and its metabolite; PP: protein 
             precipitation; LLE: liquid-liquid extraction; SPE: solid phase extraction; PM: present method 
 
EXPERIMENTAL 
Chemicals and materials 
Reference standards of clarithromycin (99.25 %) and 
clarithromycin 13C-d3 (IS, 99.58 %) were procured from 
Clearsynth Labs Pvt. Ltd. (Mumbai, India). HPLC grade methanol 
was procured from Mallinckrodt Baker, S.A.de C.V. (Estado de 
Mexico, Mexico). Analytical grade ammonium formate, formic 
acid, methyl tert-butyl ether and n-hexane were purchased from 
Merck Specialties Pvt. Ltd. (Mumbai, India). Water used in the 
entire analysis was prepared from Milli-Q water purification 
system from Millipore (Bangalore, India). Blank human plasma 
was obtained from Supratech Micropath (Ahmedabad, India) and 
was stored at –20 C until use. 
Optimized liquid chromatographic and mass spectrometry 
conditions  
A Waters Acquity UPLC system (MA, USA) was used for setting 
the reversed-phase liquid chromatographic conditions. The 
analysis of CLA and IS was performed on Acquity UPLC BEH 
C18 (50 mm × 2.1 mm, 1.7 µm) analytical column maintained at 
30°C in a column oven.  The mobile phase consisted of 
methanol-5.0 mM ammonium formate, pH 3.0 (78:22, v/v) and 
was delivered at a flow rate of 0.350 mL/min. The sample 
manager temperature was maintained at 5°C and the pressure of 
the system was 6300 psi. Quantitative analysis of CLA and IS was 
carried out on a Quattro Premier XE (USA) triple quadrupole 
mass spectrometer from Micro Mass Technologies (MA, USA). It 
was operated in the positive electro spray ionization mode and the 
ion transitions monitored for CLA and IS were m/z 748.9/158.1 
and m/z 752.8/162.0 respectively. The optimized mass parameters 
included cone gas flow: 110 L/h, desolvation gas flow: 630 L/h, 
capillary voltage: 1.4 kV, source temperature: 120 °C, desolvation 
temperature: 400 °C and extractor voltage: 4.0 V. The optimum 
values for cone voltage and collision energy were 35 V and 30 eV 
for CLA and 35 V and 32 eV for IS respectively. MassLynx 
software version 4.1 was used for data collection and peak 
integration and to control all parameters of UPLC and mass 
spectrometer. 
 
Standard stock, calibration standards and quality control 
samples  
The standard stock solution of CLA (500.0 µg/mL) was prepared 
by dissolving requisite amount in methanol. Further, intermediate 
solutions (100.0 µg/mL and 50.00 µg/mL) for spiking was 
prepared in methanol:water (60:40, v/v). Calibration standards 
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(CSs) were prepared at 0.80, 1.60, 4.00, 12.00, 36.00, 75.00, 
200.0, 400.0, 800.0, 1600 ng/mL and quality control (QC) 
samples were made at six levels, 1400 ng/mL (HQC, high quality 
control), 600.0/150.0 ng/mL (MQC-1/2, medium quality control), 
2.40 ng/mL (LQC, low quality control) and 0.80 ng/mL (LLOQ 
QC, lower limit of quantification quality control) for CLA. Stock 
solution (100.0 µg/mL) of the internal standard was prepared by 
dissolving 1.0 mg of clarithromycin 13C-d3 in 10.0 mL methanol. 
Its working solution (100 ng/mL) was prepared by appropriate 
dilution of the stock solution in methanol:water (60:40, v/v). All 
standard stock and working solutions used for spiking were stored 
at 5 °C, while CSs and QC samples in plasma were kept at -70 °C 
until use.  
Protocol for sample preparation 
Prior to analysis, all frozen subject samples, calibration standards 
and quality control samples were thawed and allowed to 
equilibrate at room temperature. To an aliquot of 100 µL of 
plasma sample, 25 µL of internal standard was added and vortexed 
for 10s. Further, 2.0 mL of n-hexane: methyl tert-butyl ether 
(20:80, v/v) solvent mixture was added and vortexed for another 
1.0 min. The samples were then centrifuged at 13148 × g for 5 min 
at 10°C. The organic layer was separated and collected in ria vials, 
followed by evaporation of the samples at 50 ºC under N2 gas. 
Finally the samples were reconstituted with 250 µL mL of mobile 
phase solution, briefly vortexed and 10 µL was used for injection 
in the chromatographic system. 
Method validation procedures 
The method was validated as per the current regulatory 
requirements to establish the accuracy and precision of the method 
[21]. The parameters studied were similar to our previous work 
[22] and are described in brief.  
System suitability experiment was performed by injecting six 
consecutive injections using aqueous standard mixture of CLA 
and IS at the start of each batch to evaluate the precision for the 
measurement of area response and retention time. System 
performance was checked by measuring the signal to noise ratio 
(S/N) for the lowest concentration of the analyte in the calibration 
curve. Carryover assessment was carried out through the 
following sequence of injections, extracted blank plasma, ULOQ 
sample, two extracted blank plasma samples, LLOQ sample, and 
extracted blank plasma at the beginning of the batch.  
The selectivity of the method was investigated by analyzing eight 
individual blank plasma sources (5 normal K3EDTA, 1 
heparinized, 1 haemolysed and 1 lipemic). Each blank plasma 
sample was tested for interference by comparing with spiked 
plasma samples at LLOQ concentration of the analyte. Method 
was also assessed for interference of some commonly used 
medications by human volunteers. This included domperidone, 
paracetamol, ranitidine, diclofenac, caffeine, acetylsalicylic acid 
and ibuprofen. Their stock solutions (100 µg/ mL) were prepared 
in methanol:water (60:40, v/v), spiked with the sample and 
analyzed to check for any interference in the quantification of the 
analyte and IS.     
Five calibration curves with ten non-zero concentrations were 
prepared to determine linearity of the method. Peak area ratio 
(analyte/IS) response obtained through multiple reaction 
monitoring vs. concentration plot was drawn using linear 
regression with 1/x2 weighting. Intra-batch accuracy and precision 
were evaluated by measurement of analytes in plasma samples on 
the same day. The analytical run consisted of a calibration curve 
and six replicates of QC samples at five concentration levels. The 
inter-batch accuracy and precision were assessed by analysis of 
five separate precision and accuracy batches on three consecutive 
days. The reinjection reproducibility for retention time was also 
checked by reinjection of one entire analytical batch.   
 The extraction recovery of CLA and IS from human plasma 
was evaluated in six replicates by comparing the mean peak area 
response of pre-extraction spiked samples to those of 
post-extraction spiked samples [23]. Matrix effect, expressed as 
matrix factors (MFs) was assessed by comparing the mean area 
response of post-extraction spiked  samples with mean area of 
solutions prepared in mobile phase solutions (neat standards) with 
identical concentration. The relative matrix effect was determined 
by assessment of precision (% CV) values for slopes of calibration 
lines from eight different plasma lots [24]. For qualitative 
assessment of matrix effect, post column infusion experiment was 
performed by infusing a standard solution of CLA at 800 ng/mL 
concentration into the mobile phase at 10 µL/min post column as 
reported previously [25].   
 The stability of CLA in plasma was examined at LQC and HQC 
levels under different study conditions: bench top at 25 °C, 
freeze-thaw at -20 °C and -70 °C, wet extract (auto sampler) at  5 
°C and 25 ºC, dry extract at 5 °C, and long term stability at -20 °C 
and -70 °C respectively. The area ratio response (analyte/IS) of 
stability samples was compared against freshly prepared 
comparison standards with identical concentration. The procedure 
also included an evaluation of short term (25 ºC) and long term (5 
ºC) stability of CLA and IS in stock and working solutions.  
The ruggedness of the method was tested on two different 
columns of the same make but different batch numbers and also by 
employing different analysts using two precision and accuracy 
batches. Further, dilution reliability of the method was studied by 
analyzing six replicates samples prepared as spiked standard at 2 
times ULOQ concentration (3200 ng/mL) after five-/ten-fold 
dilution respectively. The precision and accuracy for dilution 
reliability was determined by comparing the results against freshly 
prepared calibration curve standards.   
Bioequivalence study, statistical analysis and incurred sample 
reanalysis  
A randomized single dose study was conducted for the assessment 
of bioequivalence of a test (250 mg clarithromycin tablets from a 
Generic Indian Company, India) with a reference (BIAXIN® 
FILMTAB®, 250 mg clarithromycin tablets from Abbott 
Laboratories, North Chicago, USA) formulation in 20 healthy 
subjects under fasting. The subjects were in the age group of 
18-45 years, having body mass indices of 19.5- 26.5 kg/m2. The 
study was performed according to International Conference on 
Harmonization and USFDA guidelines [26]. Each subject was 
judged to be in good health through medical history, physical 
examination and routine laboratory tests. Subjects were informed 
of the aims and risks involved in the study and their written 
consent was obtained. After overnight fasting, the subjects were 
administered a single dose of test and reference formulations with 
240 mL of water after recommended wash out period of 7 days. 
Blood samples were collected at 0.00 (pre-dose), 0.33, 0.67, 1.00, 
1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.0, 4.5, 5.0, 5.5, 6.0, 
8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 72.0 h in K3-EDTA 
vacutainers. Plasma was separated by centrifugation and kept 
frozen at -70°C until analysis.    
For the purpose of bioequivalence analysis, Cmax, AUC0-72h and 
AUC0-inf were considered as primary variables. The 
pharmacokinetic parameters of CLA were estimated by 
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non-compartmental analysis using WinNonlin® software version 
5.3 (Pharsight Corporation, Sunnyvale, CA, USA). The statistical 
analysis for pharmacokinetic parameters included descriptive 
statistics, analysis of variance and two one-sided tests for 
bioequivalence using SAS® software version 9.2 (SAS Institute 
Inc., Cary, NC, USA). Descriptive statistics involved calculation 
of least square geometric mean for Cmax, AUC0-72, and AUC0-inf. 
To determine whether the test and reference formulations were 
pharmacokinetically equivalent, Cmax, AUC0-72, and AUC0-inf and 
their ratios (test/reference) were assessed using log transformed 
data; their means and 90% confidence intervals (CIs) were also 
calculated. The formulations were considered 
pharmacokinetically equivalent if the difference between the 
compared parameters was statistically non-significant (P ≥ 0.05) 
and the 90% CI for these parameters were within 0.8 to 1.25.  
The reproducibility of the assay was assessed by reanalysis of 100 
subject samples. The samples selected were mainly near the Cmax 
and the elimination phase in the pharmacokinetic profile of the 
drug. The results obtained were compared with the data obtained 
earlier for the same sample using the same procedure. According 
to the acceptance criterion, at least two-thirds of the original 
results and repeat results should be within 20% of each other [27]. 
  
RESULT AND DISCUSSION 
Method development  
The present work was intended to improve upon the existing 
UPLC-MS/MS method [13] with respect to the sensitivity, 
analysis time and plasma sample volume for reliable 
determination of CLA in human plasma. Mass spectrometric 
conditions like collision energy, cone voltage and capillary 
voltage were suitably optimized to obtain maximum sensitivity for 
CLA and CLA 13C-d3 (IS). Unlike other methods which 
employed a general IS, a deuterated IS was used for better 
accuracy and precision of the obtained data. MS/MS analysis was 
done using electrospray ionization in the positive mode to achieve 
high selectivity and a good linearity in regression curves. The full 
scan mass spectra for CLA and IS predominantly contained 
precursor [M+H]+ ions at m/z 748.9 and 752.8 respectively. The 
most abundant and consistent product ions in Q3 MS spectra for 
CLA and IS were observed at m/z 158.1 and 162.0 respectively 
(Figure 1). These product ions were formed by the breaking up of 
glycosidic bond to obtain fragments containing tertiary amino 
group from the protonated precursor ions. A dwell time of 100 ms 
for both the compounds was sufficient to obtain sufficient to 
obtain at least 23 data points for quantification. The current 
UPLC-MS/MS method was more sensitive (0.8 ng/mL) compared 
to all reported methods for CLA.   
Sample preparation is crucial for reliable quantitation of drugs in 
biological samples. Several reported methodologies have adopted 
either protein precipitation (PP) [5, 10, 12, 15] or liquid-liquid 
extraction (LLE) [6, 7, 13] for sample clean-up. Thus, PP was 
initially tested with acetonitrile and methanol as discussed earlier 
[10, 15]. However, due to significant matrix effect the recovery of 
CLA was very poor (40-50 %), especially at LLOQ and LQC 
levels.  
 
 
 
 
Figure 1 Product ion mass spectra of (a) clarithromycin (m/z 748.9 
→ 158.1) and (b) internal standard, clarithromycin 13C-d3 (m/z 
752.8 → 162.0) in the scan range 100-800 amu and in the positive 
ionization mode. 
 
Thus, LLE was tried in different solvents systems like diethyl 
ether, methyl tert-butyl ether, n-hexane and ethyl acetate as the 
CLA has high logP value of 3.2. Further, in our effort to have an 
efficient solvent extraction protocol for CLA and IS their 
combinations were also tested. After several trials it was found 
that n-hexane:methyl tert-butyl ether (20:80, v/v) was the best 
extraction solvent system for quantitative and precise recovery of 
the analyte and IS from plasma samples. Only 100 µL plasma 
sample was used for processing unlike the other UPLC-MS/MS 
method [13] which employed 200 µL sample. 
The nature of mobile phase and its composition, buffer pH and 
flow rate was rigorously optimized on UPLC BEH C18 (50 mm × 
2.1 mm, 1.7 µm) analytical column so as to have adequate detector 
response and acceptable peak shape. Initially, organic diluents like 
acetonitrile/methanol along with acidic buffers (ammonium 
formate-formic acid/ammonium acetate-acetic acid) in the pH 
range of 3.0-5.5 were tested. Additionally, the concentration of 
ammonium formate and ammonium acetate was also tested, 
including different flow rates (0.250, 0.300, 0.350 and 0.400 
mL/min) for adequate response. It was found that methanol and 
ammonium formate-formic acid buffer provided superior 
response compared to acetonitrile and ammonium acetate-acetic 
acid buffer. Thereafter, their ratio was adjusted for adequate 
retention, response and better peak shape for CLA and IS. The 
best chromatographic conditions were obtained with methanol 
and 5.0 mM ammonium formate, pH 3.0 adjusted with 0.1% 
formic acid (78:22, v/v) as the mobile phase at a flow rate of 0.350 
mL/min. These conditions afforded a run time of 1.5 min with 
retention times of 1.01 and 1.02 min for CLA and IS respectively. 
This analysis time was shorter compared to the existing 
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UPLC-MS/MS method. The reinjection reproducibility (% CV) of 
retention times for CLA was ≤ 0.91 % for one entire batch on the 
same column. Clarithromycin 13C-d3, used as IS in the present 
work gave excellent results for accuracy and precision at each QC 
level. The multiple reaction monitoring (MRM) chromatograms 
illustrated in Figure 2 of extracted blank plasma (double blank), 
blank plasma fortified with IS, CLA at 0.8 ng/mL and IS and a 
subject sample at Cmax demonstrates the overall performance and 
selectivity of the method.  
 
Figure 2 Representative MRM ion-chromatograms of (a) double 
blank plasma without analyte and IS, (b) blank plasma with 
working solution of clarithromycin 13C-d3 (m/z 752.8 → 162.0), 
(c) clarithromycin (m/z 748.9 → 158.1) at LLOQ and IS, (d) 
clarithromycin in real subject sample at Cmax and IS after 
administration of 250 mg dose of clarithromycin. 
 
Method validation results 
The precision (% CV) of system suitability test was observed in 
the range of 0.26 to 0.51 % for the retention time and 0.84 to 1.28 
% for the area response for CLA and IS, while the signal to noise 
ratio for system performance was ≥ 20. Carry-over evaluation was 
performed in each analytical run so as to ensure that it does not 
affect the accuracy and the precision of the proposed method. The 
column and auto-sampler carry-over evaluation showed negligible 
carry over in blank plasma (≤ 0.38 % of LLOQ sample) after 
subsequent injection of ULOQ sample (chromatograms not 
shown) at the retention time of CLA and IS.  
There was adequate linear correlation between the CLA 
concentration and the response over the concentration range of 
0.80-1600 ng/mL with correlation coefficient (r2)  0.9998. The 
mean linear equation for the calibration curves was y = (0.001632 
± 0.000004)x - (0.000013 ± 0.000011). The accuracy and 
precision (%CV) observed for the calibration curve standards 
ranged from 97.7 to 101.7 % and 1.03 to 2.90 % respectively. The 
analytical method was shown to be selective based on absence of 
any analytical signals at the retention time of CLA and IS in ten 
different batches of blank plasma. The intra-batch and inter-batch 
precision and accuracy results were within the stipulated range of 
±15 % of the nominal concentration and ˂ 15 % CV of the mean 
values as shown in Table 2.  
 
 
Table 2 Intra-batch and inter-batch precision and accuracy data for clarithromycin 
Nominal 
concentration 
(ng/mL) 
Intra-batch (n = 6; single batch) Inter-batch (n = 30; 6 from each batch) 
Mean conc 
found (ng/mL) 
% CV % 
Accuracy 
Mean conc 
found (ng/mL) 
% CV % Accuracy 
HQC (1400) 1405.6 2.80 100.4 1393.0 1.28 99.5 
MQC-1 (600.0) 613.2 3.23 102.2 585.6 3.59 97.6 
MQC-2 (150.0) 147.5 2.91 98.3 154.3 2.84 102.9 
LQC (2.40) 2.484 2.89 103.5 2.374 2.94 98.9 
LLOQ QC (0.80) 0.774 4.85 96.8 0.825 3.68 103.2 
                     CV: coefficient of variation; HQC: high quality control; MQC: medium quality control;  
                     LQC: low quality control; LLOQ QC: lower limit of quantitation quality control 
Table 3 Extraction recovery and matrix factor for clarithromycin 
 
 
QC level 
 
Area response (replicates, n = 6) % Extraction 
recovery, (B/A)  
Matrix factor 
A 
(post-extraction 
spiking) 
B 
(pre-extraction 
spiking) 
C (neat 
samples 
in mobile 
phase) 
Analyte IS Analyte 
(A/C) 
IS IS-normalized 
LQC 2309 2205 2127 95.5  97.0 1.085 1.077 1.007 
MQC-2 148124 142127 136189 96.0  96.5 1.087 1.082 1.004 
MQC-1 586876 566554 549738 96.5  97.4 1.067 1.071 0.996 
HQC 1371549 1328753 1295364 96.9  95.9 1.058 1.067 0.991 
IS: Internal standard; LQC: low quality control; MQC: medium quality control; HQC: high    quality control. 
 
 J. of Advancement in Medical and Life Sciences                  Volume2/Issue 3                                                     ISSN: 2348-294X 6 
Matrix effect can be attributed to some undesirable effects that 
originate from a biological matrix. These components may result 
in ion suppression/enhancement, decrease/increase in sensitivity 
of analyte over a period of time, increased baseline, imprecision of 
data, drift in retention time and distortion or tailing of a 
chromatographic output. It is suggested that evaluation of matrix 
factors (MFs) can help to assess the matrix effect. Further, matrix 
effect needs to be checked in lipemic and haemolysed plasma 
samples in addition to normal K3EDTA plasma. MFs can be 
determined from the peak area response for the analyte and IS 
separately, while the ratio of the two factors yields IS-normalized 
MF. The IS-normalized MFs using stable-isotope labelled IS 
should be close to unity because of the similarity in the chemical 
properties and elution times for the analyte and IS. The extraction 
recovery and matrix factors for CLA are presented in Table 3. 
The mean extraction recovery for CLA and IS was 96.2 and 96.7 
% respectively. The relative matrix effect in eight different plasma 
sources was evaluated by calculation of precision (% CV) of the 
slopes of calibration lines (Table 4).  
Table 4 Relative matrix effect in eight different lots of human 
plasma for clarithromycin 
Plasma lot Slope 
Lot-1 (K3EDTA) 0.001651 
Lot-2 (K3EDTA) 0.001615 
Lot-3 (K3EDTA) 0.001648 
Lot-4 (K3EDTA) 0.001618 
Lot-5 (K3EDTA) 0.001653 
Lot-6 (heparinized) 0.001608 
Lot-7 (haemolysed) 0.001658 
Lot-8 (lipemic) 0.001606 
Mean 0.001632 
± Standard deviation 0.000022 
% Coefficient of variation 1.36 
SD: Standard deviation; CV: coefficient of variation 
Further, qualitative assessment of matrix effect through 
post-column infusion experiment showed no ion suppression or 
enhancement at the retention time of CLA and IS in the 
chromatograms (Figure 3) 
 
 
Figure 3 Injection of extracted blank human plasma during post 
column infusion of (a) clarithromycin at 800 ng/mL and (b) 
clarithromycin 13C-d3 at100 ng/mL. 
 
The stability of analyte and IS in human plasma and stock 
solutions was examined under different storage conditions. Stock 
solutions for short term stability of CLA and IS were stable at 
room temperature up to 24 h and between 2-8 °C for a minimum 
period of 30 days. CLA in control human plasma (bench top) at 
room temperature was stable for at least 20 h at 25°C and for 
minimum of five freeze and thaw cycles. Autosampler (processed 
sample) stability of the spiked quality control samples was 
determined up to 52 h. Similarly, dry and wet extract stability of 
the samples was ascertained up to 24 h and 48 h respectively. 
Long term stability of the spiked quality control samples remained 
unchanged up to 176 days. The % change values for different 
stability experiments at LQC and HQC levels in plasma are shown 
in Table 5. 
Table 5 Stability results of clarithromycin in plasma under various 
conditions (n = 6) 
Storage 
conditions 
QC 
Level 
Nominal 
conc. 
(ng/mL) 
Mean stability 
sample 
(ng/mL) ± SD 
Change 
(%) 
Bench top 
stability  
at 25 °C, 20 h 
HQC 1400 1404.80 ± 37.07 0.34 
LQC 2.40 2.407 ± 0.070 0.31 
Freeze-thaw 
stability  
at -20 °C 
HQC 1400 1410.60 ± 38.93 0.76 
LQC 2.40 2.409 ± 0.037 0.39 
Freeze-thaw 
stability  
at -70 °C 
HQC 1400 1391.80 ± 37.85 -0.59 
LQC 2.40 2.390 ± 0.046 -0.42 
Autosampler 
stability 
 at 4°C,52 h 
HQC 1400 1397.60 ± 39.68 -0.39 
LQC 2.40 2.382 ± 0.057 -0.72 
Dry extract 
stability  
at 2-8°C, 24 h 
HQC 1400 1408.80 ± 37.79 0.63 
LQC 2.40 2.386 ± 0.042 -0.57 
Wet extract 
stability  
at 2-8°C, 48 h 
HQC 1400 1389.00 ± 40.70 -0.79 
LQC 2.40 2.411 ± 0.039 0.49 
Long term 
stability  
at -20 °C, 176 
days 
HQC 1400 1392.60 ± 32.78 -0.53 
LQC 2.40 2.404 ± 0.031 0.18 
Long term 
stability   
at -70 °C, 176 
days 
HQC 1400 1406.60 ± 24.26 0.47 
LQC 2.40 2.394 ± 0.026 -0.22 
 SD: standard deviation; n: number of replicates; HQC: high 
quality control;  
  LQC: low quality control 
100
samples comparisonMean 
samples comparisonMean –  samplesstability Mean 
%Change   
 
The precision (% CV) and accuracy values for two different 
columns ranged from 2.12 to 3.34 % and 96.1 to 103.9 % 
respectively at all five quality control levels. For the experiment 
with different analysts, the results for precision and accuracy were 
within 1.64-3.41 % and 97.6 to 100.1 % respectively at these 
levels. The dilution integrity experiment was performed with an 
aim to validate the dilution test to be carried out on higher analyte 
concentration above the upper limit of quantification (ULOQ), 
which may be encountered during real subject sample analysis. 
The precision and accuracy values for 1/2th and 1/10th dilution 
ranged from 2.97 to 4.57 % and 96.9-101.3 % respectively for 
CLA.  
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Application of the method in healthy human subjects  
The validated method was successfully applied for the assay of 
CLA in 20 healthy Indian males. Figure 4 shows the plasma 
concentration vs. time profile of clarithromycin after oral 
administration of 250 mg dose under fasting.  
 
Figure 4 Mean plasma concentration-time profile of 
clarithromycin after oral administration of test (250 mg tablets 
from a Generic Indian Company, India) with a reference 
(BIAXIN® FILMTAB®, 250 mg tablets from Abbott Laboratories, 
USA) formulation to 20 healthy subjects. 
Approximately 900 samples including the calibration and QC 
samples with volunteer samples were run and analyzed during a 
period of 5 days and the precision and accuracy for calibration and 
QC samples were well within the acceptable limits. The important 
pharmacokinetic parameters, maximum plasma concentration 
(Cmax), area under the plasma concentration-time curve from 0 to 
72 h (AUC0-72), area under the plasma concentration-time curve 
from zero hour to infinity (AUC0-inf), time point of maximum 
plasma concentration (Tmax), half life of drug elimination during 
the terminal phase (t1/2) and elimination rate constant (Kel) were 
calculated for the test and reference formulations and are 
presented in Table 6. The Tmax and t1/2 values were in agreement 
with a reported study in healthy Indian subjects [17]. 
Table 6 Mean pharmacokinetic parameters after oral 
administration of 250 mg clarithromycin tablet formulation in 20 
healthy Indian subjects under fasting. 
Parameter  Test  
(Mean ±SD) 
Reference  
(Mean ±SD) 
Cmax (ng/mL)  700.15 ± 223.27 711.09  ± 214.82 
AUC 0-72 h (h. ng/mL)  8844.2 ± 345.54 9077.3 ± 356.18 
AUC 0-inf (h. ng/mL)  8915.5 ± 399.35 9152.2 ± 389.79 
Tmax (h)  4.07 ± 1.02 4.01 ± 1.09 
t1/2 (h)  9.01 ± 2.15 9.39 ± 2.78 
Kel (1/h)  0.172 ± 0.005 0.170 ± 0.007 
   SD: standard deviation 
Further, the 90 % confidence interval (CI) of individual ratio 
geometric mean for test/reference was within 80-125 % for 
AUC0-72, AUC0-inf and Cmax (Table 7). These observations confirm 
the bioequivalence of the test sample with the reference product in 
terms of rate and extent of absorption.  
 
Table 7 Treatment ratios and 90% CIs of natural log (Ln)-transformed parameters of test and reference tablet formulations of 
clarithromycin in 20 healthy subjects under fasting. 
Parameter  Ratio 
(test/reference),% 
90% CI 
(Lower – Upper) 
Power Intra subject 
variation, % CV 
Cmax  98.5 95.1-102.8 0.9999 3.49 
AUC 0-72 h  97.4 95.2-100.5 0.9995 5.72 
AUC 0-inf  97.2 94.7-102.2 0.9998 4.25 
                          CV: coefficient of variation 
 
 
The incurred sample reanalysis (ISR) results showed % change 
values to be within ±13 % for CLA for selected samples. This 
confirms the reproducibility of the proposed method. 
 
CONCLUSIONS 
 A highly sensitive and rapid UPLC-MS/MS method for the 
determination of CLA in human plasma has been developed and 
fully validated. The method was shown to be selective and free 
from matrix interference as evident from the results of 
post-column infusion, IS-normalized matrix factors and relative 
matrix effect in different plasma lots. The validation results 
indicate good linearity, accuracy and precision, recovery and 
stability of CLA in human plasma. With twofold dilution 
reliability, it is possible to extend the upper limit of quantitation to 
3200 ng/mL.  The developed method was successfully applied to 
analyze CLA concentration in pharmacokinetic study. Further, an 
incurred sample reanalysis of 100 selected samples confirms the 
reproducibility of the proposed method, which is not reported in 
any previous method. 
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